Paradigm Biocapital Advisors’s Revolution Medicines RVMD Stock Holding History

Paradigm Biocapital Advisors’s Portfolio RVMD Stock Details RVMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.19B	Sell	6,361,323 -294,380	-4%	-$43M	22.31%	1
2026 Q1	$647M	Buy	6,655,703 +11,300	+0.2%	+$1.14M	13.23%	2
2025 Q4	$529M	Buy	6,644,403 +421,112	+7%	+$27.6M	13.51%	2
2025 Q3	$291M	Buy	6,223,291 +130,000	+2%	+$5.09M	8.27%	4
2025 Q2	$224M	Sell	6,093,291 -84,820	-1%	-$3.26M	9.57%	4
2025 Q1	$218M	Sell	6,178,111 -375,000	-6%	-$15.2M	10.01%	3
2024 Q4	$287M	Buy	6,553,111 +1,239,022	+23%	+$62.5M	9.97%	4
2024 Q3	$241M	Buy	5,314,089 +55,000	+1%	+$2.39M	8.15%	4
2024 Q2	$204M	Buy	5,259,089 +2,344,114	+80%	+$87.6M	7.81%	4
2024 Q1	$93.9M	Buy	+2,914,975	New	+$86.4M	3.31%	13

Other funds holding RVMD

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

DGM

Darwin Global Management St. Helier, Jersey $3.76B AUM 342.13% 1-Year Est. Return

Jupiter Topco New York $245B AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Paradigm Biocapital Advisors's RVMD Position: Q2 2026 in Review

Paradigm Biocapital Advisors reduced its Revolution Medicines (RVMD) stake by 4.4% in Q2 2026, selling an estimated $43M and leaving 6,361,323 shares worth $1.19B. The position accounts for 22.31% of the portfolio, ranked #1.

Paradigm Biocapital Advisors first reported a position in RVMD in Q1 2024 and has held it in 10 quarters since. 690 funds tracked by Wall St. Rank hold RVMD as of Q2 2026.

Paradigm Biocapital Advisors held 6,361,323 shares of Revolution Medicines worth $1.19B as of Q2 2026.
Paradigm Biocapital Advisors sold 294,380 Revolution Medicines shares in Q2 2026, an estimated $43M.
Revolution Medicines made up 22.31% of Paradigm Biocapital Advisors's portfolio in Q2 2026, its #1 holding.
Paradigm Biocapital Advisors first reported a position in Revolution Medicines in Q1 2024 and has held it in 10 quarters since.
690 funds tracked by Wall St. Rank held Revolution Medicines as of Q2 2026.

Based on Paradigm Biocapital Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.